NXGN - NextGen Healthcare Inc. (NXGN) Q1 2024 Earnings Call Transcript
2023-07-24 18:44:08 ET
NextGen Healthcare, Inc. (NXGN)
Q1 2024 Earnings Call Transcript
July 24, 2023 05:00 PM ET
Company Participants
James Hammerschmidt - SVP, Finance & Investor Relations
David Sides - CEO, President & Director
James Arnold - EVP & CFO
Conference Call Participants
Jeff Garro - Stephens Inc.
Jack Wallace - Guggenheim
Sean Dodge - RBC Capital Markets
Jailendra Singh - Truist Securities
Jessica Tassan - Piper Sandler
Presentation
Operator
Welcome to the NextGen Healthcare Fiscal 2024 First Quarter Results Conference Call. Hosting the call today from NextGen are David Sides, President and Chief Executive Officer; and Jamie Arnold, Chief Financial Officer. Today's call is being recorded. All lines have been placed in listen-only mode. The floor will be open for questions following the presentation. [Operator Instructions]
At this time, I'd like to turn the call over to James Hammerschmidt, Senior Vice President of Finance and Investor Relations of NextGen. James, you may begin.
James Hammerschmidt
Thank you, operator. Before we start, please note that we will be making forward-looking statements during the presentation and Q&A part of the call. These statements are based on management's current expectations and assumptions and are subject to risks and uncertainties. Factors that may cause actual results to materially differ from expectations are detailed in our earnings release and SEC filings.
This call will also reference certain non-GAAP financial measures. Information about non-GAAP financial measures, including reconciliations to US GAAP can also be found in our earnings release, which is available on our Investor Relations website.
At this time, I'd like to turn the call over to our President and CEO, David Sides.
David Sides
Thank you, James. And welcome everyone to our fiscal 2024 first quarter earnings call. I'm pleased to report solid top and bottom line results to start the new fiscal year. Building on the momentum created during fiscal 2023, company executed across all fronts and is well positioned to deliver double digit revenue growth, create operating leverage and demonstrate effective capital management.
This quarter was a testament to the strength of our business and the investments we've made to position the company for future growth. We're living our mission as the partner and trusted advisor to the practices we serve, which creates strong retention, the right to cross sell solutions and net new client wins. Our integrated platform is clearly differentiated in the market and meaningfully addresses client concerns related to financial sustainability, physician experience, interoperability and staffing constraints.
The commercial team continues to execute well. Our value proposition when serving attractive markets such as behavioral health and the integrated care is clearly resonating. Given 28% of our overall bookings came from net new clients with flagship wins in the space. Foundation to cross-sell success is ensuring our clients are leveraging the latest offerings we have, and I'm pleased to announce that the majority of our provider clients are on the latest and Cures-certified version of our product, and we have a clear line of sight to closing out the remainder.
As we were the first and remain a leader in this transition, we believe that positions us well to further accelerate Surround Solution adoption and scale. Our existing clients continue to adopt our Surround solutions, which helps them optimize their financial performance and clinical outcomes, resulting in a clear return on investment, and high growth across our diverse recurring revenue streams.
We saw strong momentum in patient volumes, which led to higher demand in the quarter than originally planned in our transaction and data revenue line, specifically our Patient Pay offering. This is a great example where we've created an integrated experience for our clients, leveraging our top ranked practice management system in partnership with a leading pair in the payment space.
And finally, we saw acceleration in our business model transition, shifting from a license and maintenance based model to a subscription managed service or transaction based model, which best aligns with how we deliver value to our client today. This transition continues to lessen our exposure to the lumpiness that comes with perpetual software licenses, which we've modeled a ramp down aligned with what we saw in the first quarter.
Now I'd like to cover the progress we're making as we invest in innovation. I mentioned in our last call that we're continuing to invest and create new organic solutions in several areas, such as data and analytics, interoperability and value based care, which is key to delivering on our growth agenda. We've made good progress over the quarter in advancing all these initiatives. We continued our investment in the Enterprise Data Cloud in partnership with AWS and Snowflake to deliver a broad set of data solutions to our customers. Working with them, we've started to unlock the value of our clients data along a few dimensions, including the ability to access and visualize clinical data for those using health quality measures.
We've found through our advanced practice intelligence and benchmarking capabilities that NextGen customers outperformed the national average in 27 of 32 CMS clinical quality measures. This is just one of many opportunities we have to leverage our core platform and help clients thrive as broader reimbursement models evolve. We completed several [fields] (ph) this last quarter with pharma and life sciences companies to support advanced clinical research studies, which expands beyond our current data partnerships.
Working with our clients and partners, we're excited about the potential to open the aperture to include new specialties with a focus on high value research studies. I’m also excited for the opportunity we've seen in our operability, specifically in supporting global clients who also have scaled needs. We are now GDPR compliant, which gives us the ability to market leading solutions like Mirth Connect for use in over 40 countries.
And finally, touching on value based care, we have been partnering with clients seeking to achieve superior quality and financial outcomes when participating in ACOs and other alternative payment models. We believe the ability to deliver insights at the point of care through the provider's current system of use remains a differentiating capability for enabling providers to take on risk. That's why I'm excited to announce that for the 2024 CMS enrollment period we successfully enrolled approximately 200 providers in [Medicare Shared Savings] (ph) ACOs, representing nearly 30,000 attributed lives. These providers are using NextGen's leading population health analytics solutions and wraparound services to improve care quality and generate significant savings.
Now turning to scale and our journey to deliver operating leverage. We see opportunity to further optimize our operating model, ensuring we have the right capabilities in place to deliver growth at scale for years to come. Focusing on cost of sales, we've made investments in the past to support the Cures upgrade effort and delivered growth in professional services. As we near the end of the upgrade cycle [indiscernible] predictable service cadence, we have plans in place to reduce our reliance on third party staff augmentation, optimize our own billable utilization, and redeploy upgraded resources to new value creation initiatives. These actions will start to be apparent in the back half of our fiscal year as our cost of sales as a percentage of revenue supporting maintenance, professional services and managed services begins to moderate.
Looking at operating expense, we've always been thoughtful on how we invest in growth oriented functions like R&D, sales and marketing, while rationalizing our G&A expense. We've evolved our product development group to a more modern agile model which should improve delivery speed and quality, while also maximizing capacity without significantly growing the organization. We continue to leverage sales development representatives to improve our client acquisition cost with higher lead to sales conversions on a more favorable cost base.
And when looking at the back office function, we've been investing in systems and automation to even further streamline how we support the business going forward. We also aim to improve the leverage we get from the vendors and strategic partners we work with. One I want to call out is our collaboration with Amazon Web Services, as we've successfully transitioned our co-lo operations for NextGen office into a secure and extensible AWS environment back in May of this calendar year. We see potential to expand partnerships like this beyond the product and do the commercial setting, taking advantage of their market place and bringing offerings into new segments and geographies where these partners already have an established channel.
I want to close by providing an update on the TSI acquisition. The integration is on track and our unified sales and marketing team had a great start to the year. We exceeded our first quarter sales targets and we're excited for the opportunity to get in front of even more clients as we plan to host over 200 attendees at our Leaders in Rheumatology Conference, where we will deepen our relationships with new and prospective clients and partners. What's exciting about the acquisition is, it further strengthens our position in the health data arena. In collaboration with our NextGen Insights team, we're actively pursuing new and expanded agreements with health data partners which will drive future revenue growth at an attractive margin.
And with that, I'd like to turn the call over to Jamie to provide an update on the financials. Jamie?
James Arnold
Thank you, David. Now turning to the first quarter results. Total bookings came in at $38.9 million, roughly flat year-over-year. Recurring bookings increased 7% as our bookings mix shifted towards higher value recurring revenue streams, which aligns with the comments David made earlier on our business model transition. There were four transactions greater than $1 million in the quarter. And as a reminder, bookings represent the annual contract value excluding renewals.
Total revenue for the quarter was $178.2 million, a 16 point percent increase year-over-year on an as reported basis and a 13% increase year-over-year on a pro forma basis. That is excluding the historical contribution of TSI pre and post-acquisition and the commercial dental assets we divested in July 2022. Recurring revenue of $163.4 million grew 17% and accounted for 92% of total revenue. Subscription services revenue of $52.5 million grew 23%. Transaction and Data Services revenue of $37.6 million grew 38% and managed services revenue of $34.8 million grew 13%. The growth was fueled by a combination of revenue from the acquisition of TSI, plus the acceleration of organic solutions.
Nonrecurring revenue for the quarter was $14.8 million, a 10% increase compared to the same quarter last year. Software revenue of $5 million was down year-over-year and under the six quarter trend, but in line with the longer term trend and in line with our internal plan. Professional services revenue of $9.9 million grew 34% as we continue to work down the backlog to bring new customers live, and there was also a benefit from closing fixed fee contracts, which resulted in a onetime uplift.
Looking forward to the next quarter, we expect revenue to be flattish sequentially, due to one fewer business days and onetime benefit in services revenue. Gross margin of 44.8% was down approximately 300 basis points compared to the same quarter last year. As discussed on last quarter's earnings call, we have made significant investment in our upgrade center of excellence and professional services, as well as a shift in product mix. Margin improvement will continue to be a focus and spend related to the upgrade center of excellence and services transformation should start to moderate towards the end of fiscal 2024.
Turning to operating expenses, net R&D expense was $20.9 million for the quarter. This is a 4% decrease compared to the same quarter last year, which included several onetime pull forward investments. SG&A of $48.2 million decreased by 2% compared to the same quarter last year. On a GAAP basis, earnings per share was $0.09 compared to $0.02 in the same quarter last year. On a non GAAP basis, earnings per share was $0.24 compared to $0.16 in the same quarter last year. Our non GAAP tax rate for the quarter was 21%.
Turning to the balance sheet, we ended the quarter with $226 million in cash, cash equivalents and marketable securities, and we had no balance outstanding on our line of credit. Free cash flow for the quarter was a negative $16.8 million and was impacted by payments for TSI customer financing sales arrangements, annual bonus and convertible debt interest payment. We expect free cash flow to be negative next quarter due to the DOJ settlement and then return to a more normalized cash flow conversion rate for the remainder of the year. We did not repurchase shares in the quarter and have $74.3 million remaining on the current share repurchase authorization.
Turning to our full year fiscal 2024 financial guidance. As noted in the press release, we are raising the bottom end of our revenue range based on the solid start to the year. We now expect total revenue to be in the range of $714 million to $722 million. Our adjusted EBITDA and non GAAP EPS guidance remains unchanged.
And now let me turn the call back to David for closing comments.
David Sides
Thank you, Jamie. NextGen continues to execute with a focus on driving growth for both us and our clients who are making the investments required to deliver long term profitability and scale. Our overall positive outlook reflects the tailwinds we created by solely focusing on ambulatory care, our resilient business model and our focus on driving shareholder value.
I want to close by thanking the 2,700 mission driven team members and thousands of clients have had the opportunity to work with on a regular basis. They are the champions behind our success and the foundation of making our equation for sustained growth and operating leverage work.
And with that, I'll turn the call back to the operator to open up for questions. Operator?
Question-and-Answer Session
Operator
Thank you. [Operator Instructions] Our first question will come from Jeff Garro with Stephens.
Jeff Garro
Yeah. Good afternoon. Thanks for taking the questions. And I appreciate the comments on bookings and given that recurring book bookings metric, that's quite helpful. I want to ask further on the demand environment. Any color that you would give on the current level of sales activity in the quarter? How your win rate is tracking and where the pipeline sits currently?
David Sides
Thanks, Jeff. So it was a good quarter from a sales perspective -- from a SaaS -- especially from a SaaS perspective. You probably saw that we went down some in perpetual, which is expected. We expect the long term to kind of go down or trend down as we really are pushing SaaS to all new clients. The environment is still good. So our pipeline looks good for this quarter, looks good for the year, looks good for continued growth, little up and down. But otherwise, from a buyer's perspective, we're feeling pretty good.
Jeff Garro
Got it. That helps. Then I wanted to ask on the profitability side of things. Any further comments on gross margins? You had some helpful comments around the timing, but maybe you could help parse out how much of the recent headwind to gross margins is attributable to revenue mix, specifically you have some strength in that transactional and data services line where presumably you have some partners in some of the areas and then how much can be attributed to that implementation work to get clients upgraded on that Cures version ahead of that looming regulatory deadline? Thanks.
James Arnold
Jeff, I would say it is -- I'm trying to -- it's probably split about evenly. The headwinds between the two factors you talked about. Clearly, we're very happy with the increase in the transactional and data services, but it does come with a lower margin. But it becomes a very sticky solution and helps round out the solutions our customers are requiring and we did see continued increased spend in the upgrade center of excellence and a little bit of increased spend on the services line. So the combination of those two are probably about half of the gross margin headwind.
Jeff Garro
Great. Thanks. I'll hop back in the queue.
James Arnold
Thank you.
Operator
Thank you. Our next question will come from Jack Wallace with Guggenheim Securities.
Jack Wallace
Hey, good evening. Thanks for taking my questions. You've got a couple of follow ups on the bookings in the quarter. Was there any impact -- have you seen any impact in the office space since the data leak? And then also with the upgrades going on, does that add any impact just from a timing standpoint of some of the Surround upgrades and add-ons, just kind of any other color there would be. Thank you.
David Sides
Yeah. Thanks. So from the office, we did see some softness in the base. So ironically, outside the base, we're getting new clients, no change, but in the base saw some softness. That started to already recover. So we're expecting that to be back to our normal steady state in this current quarter. And on the Surround, not seeing really an impact, so the Surround is still doing well for us. We should see a lot of the final clients get live on the Cures addition this quarter by October, which should set us up we think well and that a lot of synergies could come through that. For example, when somebody calls support we know the version they're on. When the salesperson calls the client, they know what version they're on. So it sets up some things for us that we think are helpful from that perspective.
As well as just adding on to the last question a little bit, in the second half of this year you'll see us start to ramp down that upgrade center of excellence. You'll see improvements on the gross margin as those -- really good people are redeployed to other parts of our business, hopefully, into more billable roles going forward, but that'll gradually go down and we're excited to keep all that great talent that we've built up here going forward.
Jack Wallace
Great. That's helpful. And then could you just comment on how the M&A pipeline has changed last quarter and just your thoughts around your private market valuations?
David Sides
I think the private market valuations are continuing to improve, at least from a buyer perspective, from our perspective. Especially if the Fed continues to raise rates. I think one of the things that people haven't factored in maybe to the rates that we thought about a lot are cost to healthcare coming through later this year in insurance premiums. I think they're going to be high and it'll set a higher floor. So, we'll see how that feeds in through next year, but at the same time we'd be a beneficiary of that and that our providers to better from some of that higher payments coming through. So it's an interesting market, and I feel that just to say, we meant this may not be the last rate increase if health care spend -- if the increases come through at 8% or 10%. And those increases are helping bring private market valuations closer to public. So we like those new prices. It also takes out some of the competition for the assets that we like from private equity because they're not -- they're financing it with debt and we're financing it with cash. So we have cash on the balance sheet to do what we want and are still seeing good opportunities out there and have a good team that's working on M&A, focused on it. So like the pipeline that we see right now.
Jack Wallace
That that's helpful. Thank you.
Operator
Thank you. Our next question will come from Sean Dodge with RBC Capital Markets.
Sean Dodge
Yes. Thanks and good afternoon. Maybe just going back to the gross margins one more time. David, you said those should begin to moderate later in the year, spend on the upgrade center winds down. When we think about how much and how quick gross margin improve. I guess, do you see a pass back to the low fifties like we saw in years past, or was that just helped a lot by license sales and now to Jamie's point, I think, around revenue mix just makes that a little bit tougher to achieve?
James Arnold
Yes, John, this is Jamie. I would say [indiscernible] 50 is a little longer. We do expect to see, as David said, we expect to see the margins start to increase in the back half of this year, but the payout to 50 is going to take a bit longer and particularly will be enhanced. When I think about the insights, the revenue that will be generated insights will be higher margin revenue and will help to lift the overall corporate margin. I think the NextGen enterprise is probably going to settle in in this kind of its current gross margin. It'll pick up a little bit over time, but not dramatically. I think the bigger improvement comes as insights revenue starts to pick up and we identified that a year ago starting to produce meaningful contribution in 2025 and 2026.
Sean Dodge
Okay. Great. That's very helpful. And then, on the bookings, is there any more color you can share on the $39 million you signed in the quarter? Was that in line with plans? Were there any kind of pushes or pull? Anything that slipped or was pulled ahead from adjacent quarters? And then maybe give us a sense of the kind of cadence you need there in order to achieve the guidance for the year? Is $39 million a quarter good enough, or do you need something a little bit higher than that going forward?
David Sides
We need something higher than that going forward. Certainly for -- especially, when you think out till 2025. I mean, we kind of talked about that before in the first quarter. The first quarter does feed into Q3 and Q4. But once we get to the third quarter, we're really talking about the following year. And the beauty of our recurring business model is 91%, like we have really good visibility. So people are like, how do you know that your confidence around your kind of revenue forecast is because, it's still recurring in nature. But we need better than $39 million in Q2 and we're -- the current forecast looks better than that. So we're not nervous about that. But you're starting -- when you get into Q3 really setting up for 2025. So this quarter was good. Next quarter should be better. We feel good still about the year. And those latter half of this year's bookings will really be about how do we continue the growth at double digits in 2025.
Sean Dodge
Okay. Great. Thanks again.
David Sides
Thanks.
Operator
Thank you. Our next question comes from Jailendra Singh with Truist Securities.
Jailendra Singh
Thank you and thanks for taking my questions. I actually want to double click on the data you shared around 200 providers and 30,000 attributed lives for 2024 CMS enrollment in MSSP and ACO products. A few questions there. First, how many of these 200 providers were you existing clients versus clients who are working with you just on value based care or these MSSP solutions? And second, maybe can you dig a little bit deeper on the key differentiation you guys have in your solutions compared to several other vendors out there doing, like, single value based care solutions?
David Sides
Thanks, Jailendra. So they're all existing clients. So everyone we've targeted so far has been existing. And what we're bringing is, we're bringing them the tech and the technology and insights integrated into the workflow so that they can actually achieve those savings without having to do a lot of work, right? And what I mean by that is, so all of our population health applications and analytics, we bring that kind of face up in the application as they're going through a clinical encounter with a patient. We're telling them, you need to check the following things to get the outcomes that will generate the better shared savings. So that's what differentiates us. We're not -- some places are taking lots of tech and then putting it together, we're able to bring all of our tech to it and bring with that some of the clinical change support. And importantly too, I'd point out that we have a proven model here. So we've seen us put out press releases with some of our clients that are generating $100 million in shared savings. We're learning from those clients and we're learning together and we're further refining our models to do better in this construct.
Jailendra Singh
It's kind of related to that. I think there was a proposal a couple of weeks back from CMS around some changes to the program and I know it might be a little early, but just curious if you had any early conversation with any provider clients because it seems like CMS expects some more participation and more lives to be attributed because of those changes. Just curious like have you heard anything in the last couple of weeks or so?
David Sides
We haven't heard anything in the last couple of weeks. We still have time to sign up more providers. So we're optimistic that this won't be the final number that we end up at. But we haven't heard it come through the marketplace yet from those changes.
Jailendra Singh
Okay. And one last one. On the free cash flow trend, I think you talked about that. So just any guidance you can provide for the year, like any number just to make sure we are in the ballpark?
James Arnold
No. We tried to share that for next quarter we're expecting it to be negative because of the cash payment. Almost $33 million went out with -- on the cash payment related to the DOJ issue. And so, obviously, that will be negative. I believe afterwards we will expect cash conversions in the back half of the year and I think of it is probably 50% of EBITDA as we are able to give you a pretty good target area.
David Sides
But for the year, still generating free cash flow on the entire year. Limited free cash flow for the entire year.
Jailendra Singh
All right, guys. Thanks a lot.
Operator
Thank you. [Operator Instructions] Our next question comes from Jessica Tassan with Piper Sandler.
Jessica Tassan
Hi. Thank you guys for taking the question. So I have a few more bookings related ones. Hopefully, you can bear with me. So are the majority of the 72% of bookings from existing customers coming from customers who are upgrading to spring 2021? And if so, just is the completion of that upgrade cycle going to moderate the volume of existing customer bookings? Or are you seeing kind of same-store sales in the month and years subsequent to the upgrades?
David Sides
So the -- I mean, the 72% are from the base and now the majority of the base is on the Cures addition. So, I guess, it stands the reason that that's where -- but it's not because of the Cures Act addition kind of absence or presence, that's driving the bookings probably. It's just do they need these things? From an implementation perspective, certainly getting easier that almost everyone is on the Cures addition. So when implementation goes to check, it's whatever it is, you can put it on this where, I think, probably two years ago without that. There are some newer Surround solutions that require that. That's pretty much all there now. So there's no -- there's less work to do to implement at this point because people are all on -- most clients are on the same release at this point.
Jessica Tassan
Got it. So just the bookings from existing customers, those are kind of coming through irrespective of the status of the upgrade and should continue to?
David Sides
Yes. I think so.
Jessica Tassan
Got it. And then just any ambulatory market kind of broadly. Do you have any sense of what practices are now 2015 Cures update compliant and what does that mean for just net new bookings prospect? Basically, does a recent update or compliance with the 2015 Cures update mean that a competitive client would be harder to convert or is that kind of a neutral factor or irrelevant to competitive conversion?
David Sides
I think it's for somebody if they're not on it, I think it's a positive for us in that -- if you're not on it, we could get you live by the deadline still. So we'd be happy to take any of those clients through the conversion process to get them live in time. So that is still good for us. And I think that's mainly a problem on the lower ends. Most of our larger practice competitors are certified by now. Those they're not upgraded, we'd still offer them an opportunity to come to NextGen. So -- but if they're already on in addition, we could still get them to come to NextGen or not. But the ones that aren't, I think there's still probably some movement to happen there in the market.
Jessica Tassan
Got it. And so then would you expect kind of the mix of bookings or just the pace of bookings from net new customers to moderate or that should remain strong despite the market generally having upgraded to be compliant?
David Sides
Yeah. I think it stays strong like you've seen it. We've been very consistent around 25%. We did a little bit better this quarter, 28%. But it's consistent. And the nice part about those clients is, they're bringing a lot of applications and Surround solutions at once, always hosted. So another way of saying that is, they're buying everything and it makes them sticky. So the part that we like about that is, we see the more like those things, the more solutions we get installed stickier they become and then new clients that are coming to us are buying everything at once. So they're sticky from the start, which, if you think about our base, they may have started somewhere 10 years ago, we've been moving them along over time. It's nice that our sales process is mature enough to sell everything at once and create a very sticky client right from the start.
Jessica Tassan
Got it. That's really helpful. And my final one would just be, are the providers that you all signed so far for MSSP. Are those providers who are already participating? And if so, what were they using previously to support their participation in MSSP? Thanks again.
Jessica Tassan
Yes, it's a good question. So thanks, Jessica. Most of them are new to -- new to the MSSP process, but we did have some conversions from competitors that aren't our normal competitors, right? So it's not like we converted them from [indiscernible] or whoever, we converted them from the kind of that different class of competitor that is still yet to prove out profitability of their business model. And the way we're looking at it is, we're trying to create a profitable business model right from the start with the very first 200 providers. So it's one of the differentiated way we're going to market is that, we're not spending, it's going to be profitable from the start. Let me just say that. We're not spending tons of money to make an unprofitable business model. We'd rather move into size and scale for our providers and we think there's a lot of movement here, but we're moving over time profitable from the start.
Jessica Tassan
Thanks again.
Operator
Thank you. And there are no additional questions at this time. I'd like to now turn the conference over to Mr. David Sides for any closing remarks.
David Sides
Thank you all for joining the conference call. We really look forward to talking to you again in the fall, in October for earning call and potentially for an Investor Day in November. So appreciate everyone's interest and we'll talk to you soon. Thanks.
Operator
Thank you. Ladies and gentlemen, this concludes today's presentation. You may now disconnect.
For further details see:
NextGen Healthcare, Inc. (NXGN) Q1 2024 Earnings Call Transcript